Company profile: Atea Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of next-generation oral antivirals for severe human viral infections, including bemnifosbuvir (AT-527), an oral direct-acting antiviral in Phase 3 for COVID-19 targeting the SARS-CoV-2 RNA polymerase; a bemnifosbuvir + ruzasvir combination in Phase 2 for HCV; and a proprietary purine nucleos(t)ide prodrug platform targeting viral RNA polymerase for mono- and combination regimens.
Products and services
- Bemnifosbuvir (AT-527): Oral direct-acting antiviral in Phase 3 for COVID-19, targeting SARS‑CoV‑2 RNA polymerase to block replication
- Oral Antiviral Platform: Proprietary purine nucleos(t)ide prodrugs engineered to target viral RNA polymerase for severe viral diseases, suitable for mono- and combination regimens
- Bemnifosbuvir + Ruzasvir: Phase 2 HCV combination therapy pairing bemnifosbuvir with ruzasvir (NS5A inhibitor) to deliver potent pan-genotypic antiviral activity targeting viral replication
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Atea Pharmaceuticals
F2G
HQ: United Kingdom
Website
- Description: Provider of novel antifungal drug discovery and development, advancing patented compounds and technologies to treat life-threatening fungal diseases. Founded on proprietary genomics technology (MycoBank) that identifies essential gene targets in fungi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full F2G company profile →
Bluejay Diagnostics
HQ: United States
Website
- Description: Provider of the Symphony automated diagnostic system using fluorescence immuno-analysis for rapid testing with integrated reagents in single-use cartridges; Symphony cartridges for blood processing and ELISA of specific biomarkers; and the Symphony IL-6 test for near-patient monitoring of disease progression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluejay Diagnostics company profile →
Utility Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antibiotics focused on combating multi-drug resistant bacterial infections in the US, including PIVYA (pivmecillinam, oral) for UTIs with a unique mode of action addressing resistance, and mecillinam (IV) targeting penicillin binding protein-2 in gram-negative bacteria and stable against β-lactamase hydrolysis, plus a development program working with the FDA to make PIVYA tablets available for uncomplicated UTIs in the US.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Utility Therapeutics company profile →
Affinium Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical research and development focused on novel anti-infective medicines, advancing FASII antibacterial programs as a new antibiotic franchise with potential for multiple products targeting the FASII pathway, supported by a broad base of long-term intellectual property.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affinium Pharmaceuticals company profile →
Stat-Sure Diagnostics
HQ: United States
Website
- Description: Provider of diagnostic testing specializing in HIV.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stat-Sure Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Atea Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Atea Pharmaceuticals
2.2 - Growth funds investing in similar companies to Atea Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Atea Pharmaceuticals
4.2 - Public trading comparable groups for Atea Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →